Von Willebrand Disease Market Report 2026

Von Willebrand Disease Market Overview

• Von Willebrand Disease market size has reached to $1.86 billion in 2025 • Expected to grow to $2.59 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Rising Prevalence Of Bleeding Disorders Fueling The Growth Of The Market Due To Improved Diagnosis And Registry Reporting • Market Trend: Advancing Therapeutics In Bleeding Prevention And Innovations Shaping The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Von Willebrand Disease Market?

Von willebrand disease (VWD) is a genetic bleeding disorder caused by a deficiency or dysfunction of von willebrand factor (VWF), a protein that helps blood clot. The severity of the disorder depends on the amount and functionality of von willebrand factor in the blood. The main types of von willebrand disease are type 1, type 2, type 3. Type 1 refers to a mild form of a bleeding disorder where a person has lower-than-normal levels of a protein called von Willebrand factor, which helps blood clot properly. The various drugs include antihemophilic factor, coagulation factor viii complex, von willebrand factor, desmopressin acetate, others with severity including mild, moderate, severe. These are distributed through various distribution channels such as hospital pharmacy, retail pharmacy, online pharmacy, others and also by various end users such as hospitals, specialty clinics, homecare, others.

What Is The Von Willebrand Disease Market Growth Forecast?

The von willebrand disease market size is expected to see strong growth in the next few years. It will grow to $2.59 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising investments in gene-based therapies, growing adoption of precision medicine approaches, expansion of patient registries and screening programs, increasing demand for long-acting therapies, advancements in recombinant drug development. Major trends in the forecast period include increasing adoption of recombinant von willebrand factor therapies, rising use of personalized treatment protocols, growing focus on early genetic diagnosis, expansion of home-based treatment options, enhanced monitoring of bleeding disorders.

What Is The Driver Of The Von Willebrand Disease Market?

The rise in the prevalence of bleeding disorders is expected to propel the growth of the von Willebrand disease market going forward. Bleeding disorders are a group of medical conditions that affect the body's ability to form blood clots, resulting in prolonged or excessive bleeding. The increase in diagnosed bleeding disorders is largely due to advancements in medical knowledge and diagnostic tools, allowing doctors and hospitals to accurately identify cases that previously went undetected. Von Willebrand disease treatment supports bleeding disorder patients by improving blood clotting, reducing excessive bleeding, and enhancing overall quality of life. For instance, in April 2024, according to the World Federation of Hemophilia, a Canada-based government organization, data collection on individuals with von Willebrand disease (VWD) began in February 2023. By December 31, 2023, a total of 999 people with VWD from 45 hemophilia treatment centers (HTCs) across 22 countries had been enrolled in the WBDR. In the same year, aggregated data were collected on 13,343 people with hemophilia (PWH) from 119 HTCs in 44 countries. Therefore, the rise in the prevalence of bleeding disorders is driving the growth of the von Willebrand disease market.

Key Players In The Global Von Willebrand Disease Market

Major companies operating in the von willebrand disease market are Pfizer Inc., Bayer AG, Sanofi S A, Takeda Pharmaceutical Company Limited, Novo Nordisk A S, CSL Behring, Grifols S A, Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co Ltd, Biotest AG, LFB S A, Bio Products Laboratory Ltd BPL, Octapharma AG, Baxter International Inc, Biogen Inc, Swedish Orphan Biovitrum AB, Roche Holding AG, BioMarin Pharmaceutical Inc, Ferring Pharmaceuticals, Alnylam Pharmaceuticals, Star Therapeutics Inc, Hemab Therapeutics, HEMA Biologics

Global Von Willebrand Disease Market Trends and Insights

Major companies operating in the von willebrand disease market are focusing on innovative therapeutics such as von willebrand factor concentrate to enhance treatment efficacy, reduce bleeding episodes, and improve patient outcomes. Von willebrand factor (VWF) concentrate is a medication used to treat and prevent bleeding in patients with von willebrand disease (VWD), a genetic bleeding disorder caused by a deficiency or dysfunction of the von willebrand factor. For instance, in April 2024, Octapharma USA Inc., a US-based pharmaceutical company announced Wilate approved by the Food and Drug Administration, a US-based government agency. This is a von willebrand factor concentrate with lyophilized powder solution for intravenous injection for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children 6 years of age and older. The FDA's orphan drug designation provides Wilate with up to seven years of market exclusivity, which is intended to encourage the development of treatments for rare diseases.

What Are Latest Mergers And Acquisitions In The Von Willebrand Disease Market?

In January 2024, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company acquired Shire plc. for $62 billion. With this acquisition, Takeda pharmaceutical company aims to strengthen its position by expanding its portfolio in rare diseases, plasma-derived therapies, and hematology, including treatments for von willebrand disease (vwd) and other bleeding disorders. shire plc. is a UK-based biotechnology company that focuses on rare diseases, including von willebrand disease.

What Defines the Von Willebrand Disease Market?

The von willebrand disease market consists of sales of antifibrinolytic drugs, harmonal therapy, and clotting factor concentrates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Von Willebrand Disease Market Report 2026?

The von willebrand disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the von willebrand disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.